http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 07:45:53 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26770969.html <p>Cantor Fitzgerald analyst Kirsten Kluska reiterated an Overweight rating and $109.00 price target on Monopar Therapeutics (NASDAQ: MNPR)</p><p>The analyst commented, "Why meet? By the time of our conference, we believe MNPR will have submitted the NDA for ALXN1840 (tiomolybdate choline) in Wilson disease (genetic disorder of copper buildup). Thus, investors should get an update on the early stages of the review, but also be able to shift some of the discussion on how to properly frame the commercial opportunity, if approved. Where we'll differentiate: We still believe there is a lot of confusion amongst investors as to the specific analyses http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26770969.html Wed, 15 Jul 2026 07:45:53 -0400 MNPR http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html si-local-file:///var/storage/secattach/20260710/26758173.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html Fri, 10 Jul 2026 18:02:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html si-local-file:///var/storage/secattach/20260710/26758173.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26758173.html Fri, 10 Jul 2026 18:02:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26741342.html si-local-file:///var/storage/secattach/20260707/26741342.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26741342.html Tue, 07 Jul 2026 14:29:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26741342.html si-local-file:///var/storage/secattach/20260707/26741342.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Monopar+Therapeutics+++++++++++++++++++Filed+by%3A+KLAUSNER+ARTHUR+J/26741342.html Tue, 07 Jul 2026 14:29:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Cittadine+Andrew/26730112.html si-local-file:///var/storage/secattach/20260702/26730112.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Cittadine+Andrew/26730112.html Thu, 02 Jul 2026 19:38:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Cittadine+Andrew/26730112.html si-local-file:///var/storage/secattach/20260702/26730112.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Cittadine+Andrew/26730112.html Thu, 02 Jul 2026 19:38:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Robinson+Chandler/26730114.html si-local-file:///var/storage/secattach/20260702/26730114.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Robinson+Chandler/26730114.html Thu, 02 Jul 2026 19:38:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Robinson+Chandler/26730114.html si-local-file:///var/storage/secattach/20260702/26730114.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Robinson+Chandler/26730114.html Thu, 02 Jul 2026 19:38:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Vu+Quan+Anh/26730115.html si-local-file:///var/storage/secattach/20260702/26730115.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Vu+Quan+Anh/26730115.html Thu, 02 Jul 2026 19:38:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Vu+Quan+Anh/26730115.html si-local-file:///var/storage/secattach/20260702/26730115.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+30++Filed+by%3A+Vu+Quan+Anh/26730115.html Thu, 02 Jul 2026 19:38:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+26++Filed+by%3A+Sweeny+Nicole/26714574.html si-local-file:///var/storage/secattach/20260630/26714574.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+26++Filed+by%3A+Sweeny+Nicole/26714574.html Tue, 30 Jun 2026 16:58:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+26++Filed+by%3A+Sweeny+Nicole/26714574.html si-local-file:///var/storage/secattach/20260630/26714574.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Monopar+Therapeutics++++++For%3A+Jun+26++Filed+by%3A+Sweeny+Nicole/26714574.html Tue, 30 Jun 2026 16:58:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Monopar+Therapeutics++++++For%3A+Jun+22++Filed+by%3A+Sweeny+Nicole/26714566.html si-local-file:///var/storage/secattach/20260630/26714566.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Monopar+Therapeutics++++++For%3A+Jun+22++Filed+by%3A+Sweeny+Nicole/26714566.html Tue, 30 Jun 2026 16:57:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Monopar+Therapeutics++++++For%3A+Jun+22++Filed+by%3A+Sweeny+Nicole/26714566.html si-local-file:///var/storage/secattach/20260630/26714566.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Monopar+Therapeutics++++++For%3A+Jun+22++Filed+by%3A+Sweeny+Nicole/26714566.html Tue, 30 Jun 2026 16:57:00 -0400 MNPR O.46563693 http://www.streetinsider.com/Corporate+News/Monopar+wins+FDA+rare+pediatric+disease+tag+for+Wilson+disease+drug/26709835.html <p>Monopar Therapeutics Inc. (NASDAQ: MNPR) announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to ALXN1840, the company's late-stage candidate for the treatment of Wilson disease.</p><p>The FDA grants Rare Pediatric Disease designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth to 18 years of age. The designation makes Monopar eligible, upon potential NDA approval, to receive a pediatric Priority Review Voucher, which can be used to obtain priority review of a subsequent marketing application or sold or transferred to another sponsor. Priority review can reduce the FDA's target http://www.streetinsider.com/Corporate+News/Monopar+wins+FDA+rare+pediatric+disease+tag+for+Wilson+disease+drug/26709835.html Tue, 30 Jun 2026 08:00:42 -0400 MNPR http://www.streetinsider.com/FDA/Monopar+wins+FDA+rare+pediatric+disease+tag+for+Wilson+disease+drug/26709835.html <p>Monopar Therapeutics Inc. (NASDAQ: MNPR) announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to ALXN1840, the company's late-stage candidate for the treatment of Wilson disease.</p><p>The FDA grants Rare Pediatric Disease designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth to 18 years of age. The designation makes Monopar eligible, upon potential NDA approval, to receive a pediatric Priority Review Voucher, which can be used to obtain priority review of a subsequent marketing application or sold or transferred to another sponsor. Priority review can reduce the FDA's target http://www.streetinsider.com/FDA/Monopar+wins+FDA+rare+pediatric+disease+tag+for+Wilson+disease+drug/26709835.html Tue, 30 Jun 2026 08:00:42 -0400 MNPR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jun+30/26709845.html si-local-file:///var/storage/secattach/20260630/26709845.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jun+30/26709845.html Tue, 30 Jun 2026 08:00:00 -0400 MNPR O.46563693 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jun+30/26709845.html si-local-file:///var/storage/secattach/20260630/26709845.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jun+30/26709845.html Tue, 30 Jun 2026 08:00:00 -0400 MNPR O.46563693 http://www.streetinsider.com/Press+Releases/Monopar+Therapeutics+Receives+FDA+Rare+Pediatric+Disease+Designation+for+ALXN1840+for+the+Treatment+of+Wilson+Disease/26709760.html <p align="justify">WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company’s late-stage candidate for the treatment of Wilson disease.</p> <p align="justify">The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth to 18 years of age. The designation provides the Company with the potential http://www.streetinsider.com/Press+Releases/Monopar+Therapeutics+Receives+FDA+Rare+Pediatric+Disease+Designation+for+ALXN1840+for+the+Treatment+of+Wilson+Disease/26709760.html Tue, 30 Jun 2026 08:00:00 -0400 MNPR http://www.streetinsider.com/Globe+Newswire/Monopar+Therapeutics+Receives+FDA+Rare+Pediatric+Disease+Designation+for+ALXN1840+for+the+Treatment+of+Wilson+Disease/26709760.html <p align="justify">WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company’s late-stage candidate for the treatment of Wilson disease.</p> <p align="justify">The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth to 18 years of age. The designation provides the Company with the potential http://www.streetinsider.com/Globe+Newswire/Monopar+Therapeutics+Receives+FDA+Rare+Pediatric+Disease+Designation+for+ALXN1840+for+the+Treatment+of+Wilson+Disease/26709760.html Tue, 30 Jun 2026 08:00:00 -0400 MNPR http://www.streetinsider.com/Analyst+PT+Change/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24117+at+BTIG/26708925.html (Updated - June 30, 2026 6:05 AM EDT) <p>BTIG analyst Jeet Mukherjee raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $117.00 (from $104.00) while maintaining a Buy rating.</p><p>The analyst commented: "We believe MNPR's regulatory outlook has improved materially ahead of a planned mid-year NDA submission for ALXN1840 for the treatment of Wilson's Disease (WD). The recent regulatory reversals for rare disease therapies including those by uniQure (QURE, Not Rated) and RegenxBio (RGNX, Not Rated) signal a turning of the page under the current FDA led by Acting Commissioner Kyle Diamantas. More importantly, the agency issued draft guidance reaffirming that http://www.streetinsider.com/Analyst+PT+Change/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24117+at+BTIG/26708925.html Tue, 30 Jun 2026 06:05:32 -0400 MNPR http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24117+at+BTIG/26708925.html (Updated - June 30, 2026 6:05 AM EDT) <p>BTIG analyst Jeet Mukherjee raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $117.00 (from $104.00) while maintaining a Buy rating.</p><p>The analyst commented: "We believe MNPR's regulatory outlook has improved materially ahead of a planned mid-year NDA submission for ALXN1840 for the treatment of Wilson's Disease (WD). The recent regulatory reversals for rare disease therapies including those by uniQure (QURE, Not Rated) and RegenxBio (RGNX, Not Rated) signal a turning of the page under the current FDA led by Acting Commissioner Kyle Diamantas. More importantly, the agency issued draft guidance reaffirming that http://www.streetinsider.com/Analyst+Comments/Monopar+Therapeutics+%28MNPR%29+PT+Raised+to+%24117+at+BTIG/26708925.html Tue, 30 Jun 2026 06:05:32 -0400 MNPR http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Monopar+Therapeutics+%28MNPR%29/26701973.html <p>H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $105.00 price target on Monopar Therapeutics (NASDAQ: MNPR).</p><p>The analyst commented: "At EAN 2026, Monopar presented new subgroup analyses from the Phase 3 FoCus trial showing greater neurologic and global clinical benefit with ALXN1840 versus standard of care in Wilson disease patients with neurologic symptoms at baseline. These data build on the previously reported Phase 3 FoCus results demonstrating superior copper mobilization versus SOC and add an important clinical layer to the ALXN1840 profile. In the neurologically symptomatic subgroup, ALXN1840 produced significant and continued improvement over the 48-week study period http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Monopar+Therapeutics+%28MNPR%29/26701973.html Mon, 29 Jun 2026 07:08:40 -0400 MNPR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jun+26/26698724.html si-local-file:///var/storage/secattach/20260626/26698724.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Monopar+Therapeutics++++++For%3A+Jun+26/26698724.html Fri, 26 Jun 2026 16:06:00 -0400 MNPR O.46563693